Full Document

FormatFile SizeNotes
PDF file 0.1 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

In mid-November, RAND conducted a survey of a nationally representative sample of adults age 18 and over (n=3,969) to collect data on the receipt of the influenza vaccine in the United States. The detailed survey data presented here will inform public health officials and other stakeholders about progress toward vaccinating adults prior to the end of the vaccination season in late winter while action can still be taken to improve vaccination rates for this flu season. In particular, it provides information on vaccination rates for adults with one or more of the following indications: age 50 or older; having a high-risk health condition; being a health-care worker; or those who have contact with or are caring for young children, elderly, or high-risk individuals.

This survey was conducted with the funding and support of GlaxoSmithKline (GSK). The research described in this report was performed under the auspices of RAND Health.

This report is part of the RAND Corporation Occasional paper series. RAND occasional papers may include an informed perspective on a timely policy issue, a discussion of new research methodologies, essays, a paper presented at a conference, or a summary of work in progress. All RAND occasional papers undergo rigorous peer review to help ensure that they meet high standards for research quality and objectivity.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.